# A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

> **NCT06371534** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 228 (estimated)

## Conditions studied

- Tumor

## Interventions

- **DRUG:** QL2109
- **DRUG:** DARZALEX FASPRO®

## Key facts

- **NCT ID:** NCT06371534
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-12
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06371534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06371534, "A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06371534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*